New daratumumab Phase 2 results posted in stage 3B AL amyloidosis; AFT-19 results still standingNov 13Weekly roundup, 5 itemsapalutamidedaratumumabUpdated
Roche posts SKYSCRAPER-01 results for tiragolumab/atezolizumab; registers Phase II Parkinson's trialNov 13Weekly roundup, 9 itemsalectinibastegolimab
FDA approves capivasertib combo for PTEN-deficient prostate cancerNov 6Regulatory decisionAstraZenecacapivasertib
AstraZeneca completes AZD4144-itraconazole PK study; posts five trial records this weekNov 6Weekly roundup, 12 itemsanifrolumab-fniaAstraZenecaUpdated
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Merck registers new MK-8644 psoriasis trial; RA and HIV/HPV vaccine trials continueOct 30Weekly roundup, 11 itemscabazitaxeldexamethasoneUpdated
Imunon agrees to sell ThermoDox rights to VoxelDox TherapeuticsOct 21Clinical readoutEikon TherapeuticsGenmab A/S
Merck registers Phase 2b trial of tulisokibart for noninfectious uveitisOct 9Weekly roundup, 8 itemsglycopyrrolateMerck & Co., Inc.
University of Washington trial of Rylaze in adult ALL remains suspended for safety reviewOct 5Clinical readoutasparaginase erwinia chrysanthemi (recombinant)-rywnGenmab A/SUpdated
Adicet Bio reports positive lupus data for prula-cel, plans pivotal trial start-up in Q4 2026Sep 28Clinical readoutRestorbio Inc.
Roche's glofitamab Phase 2 trial in untreated DLBCL posts results after primary completionAug 18Trial updateglofitamabprednisone